U.S. markets open in 1 hour 36 minutes

  • S&P Futures

    3,776.75
    -14.50 (-0.38%)
     

  • Dow Futures

    30,759.00
    -150.00 (-0.49%)
     

  • Nasdaq Futures

    12,889.50
    -11.50 (-0.09%)
     

  • Russell 2000 Futures

    2,135.50
    -18.10 (-0.84%)
     

  • Crude Oil

    52.96
    -0.61 (-1.14%)
     

  • Gold

    1,846.50
    -4.90 (-0.26%)
     

  • Silver

    25.28
    -0.52 (-2.02%)
     

  • EUR/USD

    1.2126
    -0.0029 (-0.24%)
     

  • 10-Yr Bond

    1.1290
    0.0000 (0.00%)
     

  • Vix

    23.78
    +1.57 (+7.07%)
     

  • GBP/USD

    1.3617
    -0.0074 (-0.54%)
     

  • USD/JPY

    103.7090
    -0.1070 (-0.10%)
     

  • BTC-USD

    37,667.07
    +15.95 (+0.04%)
     

  • CMC Crypto 200

    720.16
    +15.55 (+2.21%)
     

  • FTSE 100

    6,744.76
    -57.20 (-0.84%)
     

  • Nikkei 225

    28,519.18
    -179.08 (-0.62%)
     

CLASS ACTION UPDATE for NAK, KNDI and QSR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

·4 min read

NEW YORK, NY / ACCESSWIRE / January 15, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

NAK Shareholders Click Here: https://www.zlk.com/pslra-1/northern-dynasty-minerals-ltd-loss-submission-form?prid=12185&wire=1
KNDI Shareholders Click Here: https://www.zlk.com/pslra-1/kandi-technologies-group-inc-loss-submission-form?prid=12185&wire=1
QSR Shareholders Click Here: https://www.zlk.com/pslra-1/restaurant-brands-international-inc-loss-submission-form?prid=12185&wire=1

* ADDITIONAL INFORMATION BELOW *

Northern Dynasty Minerals Ltd. (NYSE:NAK)

NAK Lawsuit on behalf of: investors who purchased December 21, 2017 - November 25, 2020
Lead Plaintiff Deadline : February 2, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/northern-dynasty-minerals-ltd-loss-submission-form?prid=12185&wire=1

According to the filed complaint, during the class period, Northern Dynasty Minerals Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's Pebble Project was contrary to Clean Water Act guidelines and to the public interest; (2) the Company planned that the Pebble Project would be larger in duration and scope than conveyed to the public; (3) as a result, the Company's permit applications for the Pebble Project would be denied by the U.S. Army Corps of Engineers; and (4) as a result, Defendants' public statements were materially false and/or misleading at all relevant times.

Kandi Technologies Group, Inc. (NASDAQ:KNDI)

KNDI Lawsuit on behalf of: investors who purchased March 15, 2019 - November 27, 2020
Lead Plaintiff Deadline : February 9, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/kandi-technologies-group-inc-loss-submission-form?prid=12185&wire=1

According to the filed complaint, during the class period, Kandi Technologies Group, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Kandi artificially inflated its reported revenues through undisclosed related party transactions, or otherwise had relationships with key customers that indicated those customers did not have an arms length relationship with Kandi; (ii) the majority of Kandi's sales in the past year had been to undisclosed related parties and/or parties with such a close relationship and history with Kandi that it cast doubt on the arms-length nature of their relationship; (iii) all the foregoing, once revealed, was foreseeably likely to cast doubt on the validity of Kandi's reported revenues and, in turn, have a foreseeable negative impact on the Company's reputation and valuation; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Restaurant Brands International Inc. (NYSE:QSR)

QSR Lawsuit on behalf of: investors who purchased April 29, 2019 - October 28, 2019
Lead Plaintiff Deadline : February 19, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/restaurant-brands-international-inc-loss-submission-form?prid=12185&wire=1

According to the filed complaint, during the class period, Restaurant Brands International Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's Winning Together Plan was failing to generate substantial, sustainable improvement within the Tim Hortons brand; (2) the Tims Rewards loyalty program was not generating sustainable revenue growth as increased customer traffic was not offsetting promotional discounting; and (3) as a result, Defendants' statements about the Company's business, operations, and prospects lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP



View source version on accesswire.com:
https://www.accesswire.com/624459/CLASS-ACTION-UPDATE-for-NAK-KNDI-and-QSR-Levi-Korsinsky-LLP-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders

Latest Stories

  • U.S. Stock Futures Decline After Biden’s Spending-Bill Proposal

    (Bloomberg) -- U.S. stock futures fell, erasing early gains, as investors assessed the details of President-elect Joe Biden’s $1.9 trillion spending-bill proposal that includes $350 billion in aid to states.Contracts on the S&P 500 Index were down 0.4% as of 11:36 a.m. in London, after rising as much as 0.2% earlier. The underlying index lost 0.4% in the cash session, with investors growing concerned about the path for Federal Reserve policy now that signs of faster inflation are emerging.In Europe, the Stoxx Europe 600 Index followed through, dropping as much as 0.7%, dragged lower by energy and mining shares. The health care sector outperformed and was the only industry group firmly in the green.The Fed’s largesse and prior federal spending packages worth almost $3 trillion have powered a 70% gain in U.S. stocks from the pandemic lows in March. Biden’s plan -- long telegraphed since his election in November -- is more than double the package approved in late December, and proposes sending $1,400 to qualified individuals. It also calls for increasing the federal minimum wage to $15 an hour.U.S. stocks have pushed to record after record since the vaccine approvals and Biden’s election in November. His agenda, including ambitious aid and a follow-up plan to spend on projects such as infrastructure, got a boost Jan. 5 when Democrats won control of the Senate.Vice President Kamala Harris’ vote should help seal Democratic wins on issues that require a simple majority for passage in the evenly split upper house. However, Biden proposals including aid to states and money for health care are likely to require 60 votes, which would appear difficult to achieve.“Given the distaste Republicans have for state aid, Mr. Biden’s bipartisan hopes will be immediately tested,” Jeffrey Halley, senior market analyst with Oanda Asia Pacific Pte., wrote in a note. “And that is before the remake America bills come through with the almost certain increases in taxes.”The record climbs in stocks have stretched valuations to levels not seen in two decades, prompting warnings of a bubble that will lead to a rapid selloff. Investors have tolerated them so far because of Biden’s pledge to amp up spending not only on direct aid, but also on fighting the virus and rolling vaccines. His bill sets aside $20 billion for a national vaccine program and $50 billion to expand testing capacity.Signs of froth abound, though. In a note titled “This Is Ludicrous,” Bespoke Investment Group summed up the recent action. It cited 59 U.S.-listed stocks that are trading at prices that are more than 10 times sales and have more than doubled in the past three months. Stocks currently in that category have risen 760% since March and have a combined market capitalization of $320 billion, according to George Pearkes, global macro strategist at the firm.“Stimulus is always going to be net positive for near-term growth and profits, but the question is always how much is already priced in,” said Dan Suzuki, deputy chief investment officer at Richard Bernstein Advisors. “There’s more room for stimulus to get priced in from here, but it only adds to the cyclical recovery that will likely take place regardless of whether stimulus gets passed.”(An earlier version of this story was corrected to reflect the size of the plan in the first paragraph.)For more articles like this, please visit us at bloomberg.comSubscribe now to stay ahead with the most trusted business news source.©2021 Bloomberg L.P.

  • 8 Top Stocks Will Soar Again In 2021, Analysts Say

    Now's when many investors lament the top stocks they didn't own. But you have a second shot at some if analysts are right.

  • Value stocks are about to come out of their coma, says index fund powerhouse Vanguard

    The idea that value stocks are finally about to awaken after a decadelong slumber is almost a joke in financial circles. What is at least slightly different about Vanguard’s perspective is that its model suggests that investors have been correct in shunning value stocks, at least until the last few years. “Our research indicates that a value premium does exist and that the recent outperformance of growth stocks can be partially explained by downward-trending long-term inflation levels and the lack of material acceleration in earnings growth over the last decade,” the firm says.

  • Marijuana Stocks Jump On Democratic Senate; Are Any Good Buys Now?

    Marijuana stocks surged as a Democratic Senate adds to cannabis legalization momentum. Are any pot stocks good buys now amid profitability challenges?

  • Four things that could pop the 'rational bubble' in equities: Mohamed El-Erian

    Four things could pop the "rational bubble" in equities, says Mohamed El-Erian — even if they're not likely to happen right now.

  • Sorrento Stock Could Hit $30, Says Analyst

    The major U.S. equity-indexes are hovering around all-time highs, and a question that frequently pops up these days, is whether some companies’ valuations might be overstretched. However, some operate at the opposite end of the spectrum, and could yet offer investors untapped opportunities. H.C. Wainwright analyst Ram Selvaraju points in the direction of Sorrento Therapeutics (SRNE), as one such company. Selvaraju rates SRNE a Buy along with a $30 price target, which implies a 275% upside from current levels. (To watch Selvaraju’s track record, click here) So, what’s behind the optimistic outlook? Well, for starters, Sorrento has a stake in two cell-based immunotherapy companies that could “drive value in Sorrento shares over the coming months.” One is Celularity, a clinical-stage cell therapeutics company focused on cellular medicines for cancer, infectious diseases, and degenerative diseases. Celularity is expected to go public later this year via a SPAC merger with GX Acquisition Corp. The merged company’s equity value following the transaction’s closure will land at roughly $1.7 billion. Selvaraju estimates Sorrento's position should be worth in the $200 million region. The second company is NantKwest, which recently signed a deal to merge with ImmunityBio. The transaction is expected to close in 1H21. Sorrento owns roughly 8.2 million shares of the clinical-stage immunotherapy company. These are currently worth around $121 million, going by NantKwest’s recent share price. Additionally, the analyst highlights Sorrento’s “burgeoning portfolio of assets spanning three distinct therapeutic areas (non-opioid pain management, oncology and COVID-19).” In fact, on the Covid-19 front alone, Sorrento has taken a broad-based approach and has a long list of diagnostic, prophylactic and therapeutic offerings in the pipeline, with “updates likely to come fast and furious.” These include two rapid detection tests; COVI-STIX, for which the company filed for Emergency Use Authorization (EUA) in the U.S. in December, and COVI-TRACE, which Selvaraju claims could come in handy at any mass gathering event. “We believe that the incentive to facilitate the large-scale and indeed ubiquitous deployment of the COVI-TRACE test is extremely high and governments worldwide may seek to implement this in their respective regions,” the 5-star analyst opined. Other Covid-19 candidates include COVIGUARD - a SARS-CoV-2 neutralizing antibody, COVI-AMG - an affinity-matured version of the COVIGUARD neutralizing antibody, a neutralizing antibody cocktail named COVI-SHIELD and COVIDTRAP, an ACE2 receptor decoy, intended to imitate the mammalian ACE2 receptor that acts as the primary portal for the SARS-CoV-2 virus to penetrate human cells. It has been relatively quiet when it comes to other analyst activity. In the last three months, only 2 analysts have issued ratings. However, as they were both Buys, the word on the Street is that SRNE is a Moderate Buy. Based on the $25.50 average price target, shares could climb 219% higher in the next twelve months. (See SRNE stock analysis on TipRanks) To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analyst. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • JPMorgan posts big Q4 earnings beat, releases credit reserves amid 'economic uncertainty'

    JPMorgan delivered results that blew away analysts’ expectations even as the COVID-19 pandemic continued to exert significant headwinds on the global economy.

  • Bank of America's 8 Best Stocks to Buy in Q1

    Here are analysts' top stocks to buy in the first quarter.The S&P 500 closed out 2020 at all-time highs on optimism surrounding additional government stimulus measures and a potential global economic rebound in 2021.

  • Fastest-Growing Stocks: Square Stock Among 7 Stocks Expecting Up To 156% Growth In 2021

    What are the fastest-growing stocks to watch in 2021? Here's a list featuring GRWG stock, Square, Daqo and four other stocks expecting up to 156% growth.

  • Biden's Boom: The $30 Trillion ESG Sector Is Set To Explode In 2021

    The ESG mega-trend sent trillions of dollars pouring in last year. But the real boom could be set to take off beginning January 20th

  • Biden Stimulus, JPMorgan Chase, Tesla, Apple - 5 Things You Must Know Friday

    Stock futures fall after President-elect Joe Biden unveils a $1.9 trillion Covid-19 relief package; JPMorgan, Wells Fargo and Citigroup report earnings; Tesla gets a bull case price target of $1,250 from Wedbush.

  • Virgin Galactic, Space Stocks Soar As Tesla Bull Eyes New ETF

    Virgin Galactic and other space stocks jumped Thursday on hopes for a new space-focused exchange traded fund.

  • Trump's China tech war backfires on automakers as chips run short

    Automakers around the world are shutting assembly lines because of a global shortage of semiconductors that in some cases has been exacerbated by the Trump administration's actions against key Chinese chip factories, industry officials said. The shortage, which caught much of the industry off-guard and could continue for many months, is now causing Ford Motor Co, Subaru Corp and Toyota Motor Corp to curtail production in the United States. Automakers affected in other markets include Volkswagen, Nissan Motor Co Ltd and Fiat Chrysler Automobiles.

  • JPMorgan Says Hydrogen Stock Plug Power Trades At 'Steep Price,' Downgrades FuelCell Energy

    Hydrogen power company Plug Power Inc (NASDAQ: PLUG) is both a first mover and fast mover in the hydrogen fuel cell space, but the stock trades a "steep price," according to JPMorgan.The Plug Power Analyst: Paul Coster initiated coverage of Plug Power with a Neutral rating and $60 price target.The Plug Power Thesis: Plug Power has been an early player in the $200-billion electrification of the transportation and logistics market, Coster said in a Thursday initiation note.The company is able to back up its year of operation with a proven proton exchange membrane technology, a strong balance sheet, and large customers and partners, the analyst said.This gives the company a compelling path to make $1.2 billion in sales by 2024 and generate a profit, he said. In fact, Plug Power's recent SK Group and Renault partnerships could lift its 2024 sales outlook to $1.7 billion, and revenue growth will continue to accelerate in 2025, Coster said. Yet JPMorgan's $60 price target is based on a discounted valuation model of 60 times the EV/2025 EBITDA forecast of $534 million."Welcome to hydrogen fuel cell investing," the analyst said. Related Link: Why Plug Power's Lead In Fuel Cell, Hydrogen Space Could Create 'Outsized Winner'Why JPMorgan Is Downgrading FuelCell: Separately, Coster downgraded FuelCell Energy Inc's (NASDAQ: FCEL) stock rating from Neutral to Underweight.The stock is up 70% since the start of 2021 and more than 800% over the last year. Shares are trading at around 50 times price/forward sales and are "richly valued" compared to peers, the analyst said. "At this point we expect the stock to underperform the mean of our coverage over the next 6-12 months, though we remain constructive regarding the Alt Energy sector in general." PLUG, FCEL Price Action: Shares of Plug Power lost 4.26% in Thursday's session, closing at $66.54, while FuelCell Energy plunged 8.05% to $17.60. Photo courtesy of Plug Power. Latest Ratings for FCEL DateFirmActionFromTo Jan 2021JP MorganDowngradesNeutralUnderweight Jan 2021JefferiesInitiates Coverage OnHold Dec 2020Canaccord GenuityInitiates Coverage OnHold View More Analyst Ratings for FCEL View the Latest Analyst RatingsSee more from Benzinga * Click here for options trades from Benzinga * Plug Power CEO Highlights Democratic Senate Win, SK Contract(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Wells Fargo Earnings: What to Look For From WFC

    Wells Fargo (WFC) reports Q4 earnings before market open on January 15. Can the bank reverse falling earnings and stem rising loan losses?

  • 2 “Strong Buy” Stocks Trading at Steep Discounts

    Whether markets move up or down, every investor loves a bargain. There’s a thrill in finding a valuable stock at low, low price – and then watching it appreciate in the mid- to long-term. The key here for investors is finding options in which the risk/reward combination will work toward long-term advantage. So, how are investors supposed to distinguish between the names poised to get back on their feet and those set to remain down in the dumps? That’s what the pros on Wall Street are here for. Using TipRanks’ database, we pinpointed two beaten-down stocks the analysts believe are gearing up for a rebound. Despite the hefty losses incurred over the past 52 weeks, the two tickers have scored enough praise from the Street to earn a “Strong Buy” consensus rating. Theravance Biopharma (TBPH) We will start with Theravance, a biopharmaceutical company that focuses on developing organ-specific medications. It’s current pipeline includes drug candidates for the treatment of inflammatory lung and intestinal conditions, as well as neurogenicorthostatic hypotension. The research programs range from Phase 1 to Phase 3 trials. Theravance already has YUPELRI on the market as a COPD treatment. YUPELRI underlies the lion’s share of Theravance’s revenue, which in Q3 reach $18.3 million. This was up 47% year-over-year, and was driven by a 124% increase in YUPELRI sales. Of more immediate interest to investors is Trelegy Ellipta, GlaxoSmithKline’s new once daily inhaler medication developed as a maintenance treatment for asthma, which was approved by the FDA in September, 2020. This approval will give Theravance a slice of the income on a drug with a broad potential audience, as asthma affects more than 350 million people globally. Theravance owns royalty rights on Trelegy, with income estimated at 5.5% to 8.5% of total sales. Trelegy was initially approved in the US as the first once-daily single inhaler triple therapy for the treatment of COPD. Like many biopharmas, Theravance has high overhead and its approved drugs are at the start of their profitable lives. This keeps the net earnings and revenues down, at least for the near-term, and leads to a discount share price – TBPH has slipped 32% over the past 52 weeks. Covering the stock for Leerink, analyst Geoff Porges remains bullish on Theravance, mainly due to the combination of its robust pipeline and its approved treatments for lung diseases. “Theravance’s respiratory medicines are its key near-term valuation drivers… We still forecast ~$2.4B in WW Triple sales at peak (2027E). Beyond TBPH’s commercial/partnered assets, the company is also developing an improved JAK inhibitor (JAKi) partnered with JNJ (OP) for inflammatory bowel disease (IBD), and a norepinephrine and serotonin reuptake inhibitor (NSRI) TD-9855 (ampreloxetine) for neurogenic orthostatic hypotension (nOH). Each of these drugs leverages novel delivery of unique compounds against proven mechanisms-of-action and could offer superior safety and/or treatment effect, from their wider therapeutic windows,” Porges noted. To this end, Porges rates TBPH an Outperform (i.e. Buy) and gives it a $35 price target, implying an impressive one-year upside of 104%. (To watch Porges’ track record, click here) Overall, there are 5 reviews on file, and all are to Buy, making the Strong Buy consensus unanimous. TBPH shares are priced at $16.95, and their $33.60 average price target suggests a 97% upside from that level. (See TBPH stock analysis on TipRanks) NiSource, Inc. (NI) NiSource is a utility holding company, with subsidiaries in the natural gas and electricity sectors. NiSource provides power and gas to over 4 million customers in Indiana, Kentucky, Maryland, Massachusetts, Ohio, Pennsylvania, and Virginia. The majority of NiSource’s customers, about 88%, are in the gas sector; the company’s electric operations serve customers in Indiana only. The company saw revenues in the third quarter come in at $902 million, down from $962 in the prior quarter and $931 in the year-ago quarter. Overall, however, revenues have conformed to the company’s historic pattern: The second and third quarters are relatively low, while the top line increases with cold weather in Q4 and peaks in Q1. This is typical of utility companies in North America. Despite the lower year-over-year revenues, NiSource has felt confident enough to maintain its dividend payment, holding it steady at 21 cents per common share through 2020. This annualizes to 84 cents, and gives a yield of 3.8%. Not only has the company felt confident to pay income to shareholders, it has also felt confident to invest heavily in renewable energy resources. The company has a FY20 capital spending plan exceeding $1.7 billion, and is guiding toward $1.3 billion for FY21. These expenditures will fund ‘green’ energy projects. NI is currently trading at $21.67, a striking distance from its 52-week low. One analyst, however, thinks this lower stock price gives investors an attractive entry point today. Argus analyst Gary Hovis rates NI a Buy along with a $32 price target. This figure implies a 48% upside from current levels. (To watch Hovis' track record, click here) "NI shares appear favorably valued at 18.1-times our 2021 EPS estimate, below the average multiple of 21.6 for comparable electric and gas utilities," Hovis noted. "NiSource could also become a buyout target, as larger utilitiesand private equity firms have purchased smaller utilities because oftheir stable earnings growth and above-average dividend yields." Overall, Wall Street sees a clear path forward for NiSource – a fact clear from the unanimous Strong Buy consensus rating, based on 3 recent Buy-side reviews. The shares are selling for $21.68, and the average price target of $28.75 suggests an upside of ~32% on the one-year timeframe. (See NI stock analysis on TipRanks) To find good ideas for beaten-down stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

  • Stock market news live updates: Stock futures point to a lower open

    Stock futures fell in pre-market trading as traders considered details of President-elect Joe Biden’s newly unveiled stimulus proposal and weighed the likelihood of the package getting advanced quickly through Congress. COVID-19 concerns also flared anew, and stay-in-place restrictions tightened across parts of Europe.

  • Buy Shopify, ServiceNow, and 5 Other Cloud Stocks, Says Oppenheimer

    Analyst Brian Schwartz says that investors may need to be more selective this year after last year’s rally in cloud-software stocks.

  • Looking Into BlackBerry's Return On Capital Employed

    During Q3, BlackBerry's (NYSE:BB) reported sales totaled $224.00 million. Despite a 700.0% in earnings, the company posted a loss of $32.00 million. BlackBerry collected $266.00 million in revenue during Q2, but reported earnings showed a $4.00 million loss.What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company's ROCE. A higher ROCE is generally representative of successful growth of a company and is a sign of higher earnings per share in the future. A low or negative ROCE suggests the opposite. In Q3, BlackBerry posted an ROCE of -0.02%.Keep in mind, while ROCE is a good measure of a company's recent performance, it is not a highly reliable predictor of a company's earnings or sales in the near future.View more earnings on BBROCE is an important metric for the comparison of similar companies. A relatively high ROCE shows BlackBerry is potentially operating at a higher level of efficiency than other companies in its industry. If the company is generating high profits with its current level of capital, some of that money can be reinvested in more capital which will generally lead to higher returns and earnings per share growth.In BlackBerry's case, the ROCE ratio shows the amount of assets may not be helping the company achieve higher returns. Investors may take this into account before making any long-term financial decisions.Q3 Earnings Recap BlackBerry reported Q3 earnings per share at $0.02/share, which beat analyst predictions of $-0.01/share.See more from Benzinga * Click here for options trades from Benzinga * Why Aurora Cannabis's Stock is Trading Higher Today * Analyzing The Price Action In Acacia Communications Stock Today(C) 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Tesla stock is 'very fully priced,' says investing legend Byron Wien

    Tesla shares look fully valued to investing legend Byron Wien of Blackstone. Here's what Wien told Yahoo Finance Live.